The CRA has confirmed $7,000 in new TFSA (Tax-Free Financial savings Account) contribution room for 2026, and in case you haven’t used it but, now could be the time to take action. The simplest strategy to construct long-term wealth inside a TFSA isn’t to park money in a financial savings account incomes 3%, however to purchase high quality development shares and let compounding do the work, tax-free.
One Canadian inventory that stands out proper now could be AbCellera Biologics (NASDAQ:ABCL), a well-funded biotech approaching a significant scientific milestone and flying properly beneath the radar of most retail traders.
Supply: Getty Photos
The TFSA contribution is up by $7,000
The TFSA was launched in 2009 and has turn into probably the most versatile funding account out there to Canadians. Yearly, the CRA units a brand new contribution restrict. For 2026, that restrict is $7,000, the identical as 2024 and 2025.
Should you’ve by no means contributed, your whole cumulative room in 2026 could possibly be as excessive as $109,000, relying in your age and residency historical past.
Right here’s why that issues. Each greenback you earn inside a TFSA, whether or not from capital positive aspects, dividends, or curiosity, is totally exempt from tax. Eternally. Over a 20-or 30-year horizon, the distinction between a taxable account and a TFSA can quantity to tens of hundreds of {dollars}, particularly in case you’re holding high-growth belongings.
Why this small-cap inventory deserves a spot in your TFSA
AbCellera isn’t a family identify. But it surely’s the sort of firm that tends to reward traders who discover it early.
Based in 2012 and headquartered in Vancouver, AbCellera has spent over a decade and roughly US$1 billion constructing an end-to-end platform to find, develop, and now manufacture antibody-based medicines.
As Martin Hogan, the corporate’s Senior Director of Strategic Finance and Investor Relations, defined on the TD Cowen Healthcare Convention in March 2026, what began as a drug discovery service enterprise has developed into one thing rather more useful: a completely built-in biotech with its personal scientific pipeline.
“By far, probably the most useful factor that got here out of that was the aptitude of the workforce and the platform to pursue these targets,” Hogan mentioned. “And we’re discovering that probably the most useful software of that functionality actually is in opposition to targets that we are able to determine ourselves and pursue with inside packages.”
AbCellera’s lead program, ABCL635, is a non-hormonal remedy for moderate-to-severe sizzling flashes, recognized clinically as vasomotor signs (VMS), related to menopause.
In response to Hogan, roughly 12 million ladies in the US expertise moderate-to-severe sizzling flashes. About one in 5 of these ladies can’t tolerate or are ineligible for hormone remedy, leaving a major unmet want.
Two small-molecule medicine already available on the market handle this. However each include liver toxicity considerations and require baseline monitoring earlier than a affected person can begin remedy.
AbCellera’s antibody-based strategy is designed to keep away from these points completely, with a once-monthly auto-injectable that sufferers and physicians have constantly most popular in market analysis.
A robust steadiness sheet
AbCellera ended 2025 with roughly US$700 million in money, equivalents, and dedicated authorities funding. Its annual working money utilization is round US$120 million to US$130 million.
That offers ABCL greater than three years of runway at full pace with no need to dilute shareholders or lower packages. The corporate additionally constructed its personal clinical-grade manufacturing facility in Vancouver, which is uncommon for a biotech of this dimension.
Past the operational flexibility it supplies, Hogan identified a much less apparent benefit: as a result of sequences keep in-house reasonably than being transferred to a contract producer, AbCellera positive aspects two to 4 extra years of efficient patent safety on every drug.
AbCellera shouldn’t be a inventory for conservative traders. It’s a clinical-stage biotech. The Part II readout in Q3 will both validate or considerably set again the thesis.
However for TFSA traders with an extended time horizon and an urge for food for higher-risk, higher-reward alternatives, AbCellera has a compelling setup.
It’s a well-capitalized Canadian firm with a differentiated platform, a transparent near-term catalyst, and a pipeline designed to develop for years.
